Inozyme Pharma, Inc.
INZY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $174 | $221 | $40 | $161 |
| - Cash | $21 | $35 | $33 | $23 |
| + Debt | $47 | $47 | $7 | $3 |
| Enterprise Value | $200 | $233 | $14 | $141 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| EBITDA | -$104 | -$75 | -$66 | -$56 |
| % Margin | – | – | – | – |
| Net Income | -$102 | -$71 | -$65 | -$56 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.62 | -1.37 | -1.73 | -2.39 |
| % Growth | -18.2% | 20.8% | 27.6% | – |
| Operating Cash Flow | -$92 | -$71 | -$58 | -$48 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$92 | -$71 | -$58 | -$49 |